Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240928
Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01239745
- Locations
- 🇭🇷
University Hospital Center Osijek, Osijek, Croatia
🇭🇷University Hospital Center Split, Split, Croatia
🇪🇪North Estonia Medical Centre Foundation, Tallinn, Estonia
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT01234857
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT01202591
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 8
- Registration Number
- NCT01153672
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT01151046
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇪🇸Puerta de Hierro, Madrid, Spain
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT01149356
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 378
- Registration Number
- NCT01121549
- Locations
- 🇷🇴
Spitalul Judeţean Brasov, Brasov, Jud. Brasov, Romania
🇷🇴Spitalul Judetean Bistrita Nasaud - Sectia Oncologie Medicala, Bistrita, Jud. Nasaud, Romania
🇷🇴Spitalulul Municipal de Urgenta Roman, Roman, Neamt, Romania
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 206
- Registration Number
- NCT01047358
- Locations
- 🇰🇷
Yeung Nam University Hospital, Daegu, Korea, Republic of
🇰🇷Soon Chun Hyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of
ELBA: Exemestane and Lapatinib in Advanced Breast Cancer
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- National Cancer Institute, Naples
- Registration Number
- NCT01005641
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy
🇮🇹Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C, Napoli, Italy
🇮🇹Ospedale S. Luca ASL SA 3, Vallo della Lucania, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.